AR111288A1 - Anticuerpos anti-phf-tau y sus usos - Google Patents

Anticuerpos anti-phf-tau y sus usos

Info

Publication number
AR111288A1
AR111288A1 ARP180100620A ARP180100620A AR111288A1 AR 111288 A1 AR111288 A1 AR 111288A1 AR P180100620 A ARP180100620 A AR P180100620A AR P180100620 A ARP180100620 A AR P180100620A AR 111288 A1 AR111288 A1 AR 111288A1
Authority
AR
Argentina
Prior art keywords
antibodies
phf
tau antibodies
tau
tauopathies
Prior art date
Application number
ARP180100620A
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR111288A1 publication Critical patent/AR111288A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Abstract

Se describen anticuerpos anti-PHF-tau monoclonales y fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y el uso de los anticuerpos para tratar o prevenir afecciones tales como tauopatías.
ARP180100620A 2017-03-16 2018-03-16 Anticuerpos anti-phf-tau y sus usos AR111288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
AR111288A1 true AR111288A1 (es) 2019-06-26

Family

ID=63521020

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100620A AR111288A1 (es) 2017-03-16 2018-03-16 Anticuerpos anti-phf-tau y sus usos

Country Status (21)

Country Link
US (3) US10766953B2 (es)
EP (1) EP3596119A4 (es)
JP (2) JP7159185B2 (es)
KR (2) KR102597462B1 (es)
CN (2) CN110799531B (es)
AR (1) AR111288A1 (es)
AU (1) AU2018234709A1 (es)
BR (3) BR122023021958A2 (es)
CA (1) CA3055598A1 (es)
CL (1) CL2019002566A1 (es)
EA (1) EA201992038A1 (es)
IL (2) IL310464A (es)
JO (1) JOP20180021A1 (es)
MA (1) MA47789A (es)
MX (1) MX2019010922A (es)
PH (1) PH12019501973A1 (es)
SG (1) SG11201907754RA (es)
TW (1) TWI771389B (es)
UY (1) UY37635A (es)
WO (1) WO2018170351A1 (es)
ZA (1) ZA202101318B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
KR102471787B1 (ko) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
WO2020242963A1 (en) * 2019-05-31 2020-12-03 Eli Lilly And Company Compounds and methods targeting human tau
TWI780464B (zh) * 2019-08-06 2022-10-11 香港商新旭生技股份有限公司 結合至病理性ｔａｕ種類之抗體及其用途
AU2021251486A1 (en) * 2020-04-08 2022-12-08 Janssen Biotech, Inc. Anti-PHF-TAU antibodies and uses thereof
MX2023000695A (es) * 2020-07-14 2023-04-20 Janssen Pharmaceutica Nv Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica.
WO2022090169A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Method of safe administration of anti-tau antibody
CN116916955A (zh) * 2020-10-26 2023-10-20 詹森药业有限公司 减少人类受试者中的Tau的方法
TW202246321A (zh) * 2021-02-19 2022-12-01 日商衛材R&D企管股份有限公司 抗pt217 tau抗體
IL307170A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Anti-tau antibodies and their uses
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
EP0737208B1 (en) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
AU710952B2 (en) 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
CN1780855B (zh) 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2659820A1 (en) 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
DK2488867T3 (da) 2009-10-14 2020-11-09 Janssen Biotech Inc Fremgangsmåder til affinitetsmodning af antistoffer
CA2795799C (en) * 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
TW201216985A (en) 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
JP2014503178A (ja) * 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
JP6306513B2 (ja) * 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用

Also Published As

Publication number Publication date
CN110799531B (zh) 2023-08-04
CN117209599A (zh) 2023-12-12
CL2019002566A1 (es) 2019-12-27
WO2018170351A8 (en) 2019-12-19
US11365244B2 (en) 2022-06-21
US20180265575A1 (en) 2018-09-20
JP2020513804A (ja) 2020-05-21
TW201900682A (zh) 2019-01-01
BR122023021947A2 (pt) 2024-02-20
PH12019501973A1 (en) 2020-06-29
BR122023021958A2 (pt) 2024-02-20
CN110799531A (zh) 2020-02-14
EP3596119A1 (en) 2020-01-22
MA47789A (fr) 2020-01-22
US10766953B2 (en) 2020-09-08
US20230047413A1 (en) 2023-02-16
EP3596119A4 (en) 2021-01-13
JP2022191383A (ja) 2022-12-27
UY37635A (es) 2018-09-28
IL268700A (en) 2019-10-31
ZA202101318B (en) 2023-03-29
KR20190130133A (ko) 2019-11-21
WO2018170351A1 (en) 2018-09-20
TWI771389B (zh) 2022-07-21
BR112019019049A2 (pt) 2020-04-22
AU2018234709A1 (en) 2019-08-29
JP7159185B2 (ja) 2022-10-24
CA3055598A1 (en) 2018-09-20
KR102597462B1 (ko) 2023-11-03
MX2019010922A (es) 2019-11-08
JOP20180021A1 (ar) 2019-01-30
IL310464A (en) 2024-03-01
KR20230155025A (ko) 2023-11-09
US20210179696A1 (en) 2021-06-17
IL268700B1 (en) 2024-03-01
EA201992038A1 (ru) 2020-02-06
SG11201907754RA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CL2020002314A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CO2018003436A2 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS